The Directorate General of Drug Administration, under the Ministry of Health and Family Welfare, is the national medicines regulator. It licenses manufacturers, importers, wholesalers and pharmacies, registers medicines, medical devices and cosmetics, and monitors quality, safety, pricing and promotion. Statutory committees, such as those dealing with drug control and pricing, take key decisions. Healthcare facilities are licensed separately by the Directorate General of Health Services, and clinical trial ethics are overseen by the Bangladesh Medical Research Council. We help clients identify the right authority for each step and coordinate approvals across them so that licensing stays aligned.

It can in some cases, but the route is restricted. Bangladesh has historically favoured local manufacture, and imports of finished medicines are generally limited to products that are not produced locally or that meet specific needs, subject to registration and import permission. The foreign manufacturer normally appoints a local licensed importer or agent, and the product must be registered with DGDA before sale. Where import is not realistic, contract manufacturing or technology licensing with a Bangladeshi manufacturer may be better. We assess each product against current pharmaceutical regulation and policy before the company commits significant resources.

There is no reliable fixed period. Timing depends on the type of product, whether it is new to Bangladesh, the quality of the dossier, the committee meeting schedule and any queries raised by DGDA. New molecules and products requiring expert review can take considerably longer than generics already on the market. A complete, consistent dossier with clear answers on stability, bioequivalence where relevant, labelling and manufacturing site information reduces the risk of delay. We give a realistic estimate after reviewing the product and the dossier, and we track progress closely. Registration delay is a common pharmaceutical regulation concern.

Prices of medicines on the essential list are fixed by the regulator, while for other products manufacturers and importers generally declare prices, which the regulator may review. The rules have been revised over time, and the list of price-controlled products can change. Selling above an approved or declared price can lead to enforcement action. Pharmaceutical regulation on pricing also interacts with competition law, particularly where manufacturers coordinate on prices or distributors restrict supply. We advise on pricing submissions, contracts with distributors and responses to regulatory or competition enquiries about prices or supply practices.

Advertising prescription medicines to the general public is restricted, and promotional materials for healthcare professionals must be accurate, balanced and consistent with the registered product information. Sponsorship of doctors, conference support, samples and gifts raise anti-bribery questions under Bangladeshi law and under foreign laws that bind multinational groups. Digital promotion, including social media and influencer content, is an area of increasing scrutiny. We review promotional materials and policies, train commercial teams and advise on compliant engagement with healthcare professionals so that marketing supports sales without regulatory risk. Promotion is a frequent focus of enforcement.

As a least developed country, Bangladesh has been able to use a transition period under the WTO TRIPS Agreement that allowed it not to grant or enforce pharmaceutical patents. That flexibility is linked to LDC status, so graduation is expected to bring stronger patent obligations, subject to any transition arrangements negotiated. Local generic manufacturers will need to review their portfolios, and foreign originators may consider patent filings and licensing. We advise on the legal effect for specific products, patent strategy, freedom to operate and voluntary licensing arrangements with originators. Companies should map which products and patents might be affected.

A private hospital, clinic or diagnostic centre needs a licence from the Directorate General of Health Services, with conditions on premises, equipment, staffing and services. Other approvals typically include a trade licence, environmental clearance for waste management, fire safety certification, a pharmacy licence for an in-house dispensary and, for imaging, licensing for radiation equipment. Renewal dates should be tracked and premises kept ready for inspection. Foreign investors need to consider investment registration with Invest Bangladesh. We map the approvals for each project and keep the licence portfolio current. An in-house pharmacy brings the hospital within pharmaceutical regulation as well.

Act quickly and keep records. Confirm the scope and reasons for the order, identify affected batches, notify distributors and pharmacies, stop further supply and preserve samples and documents. Investigate the root cause with the manufacturing site and review whether other products or batches are affected. Communication with the regulator should be accurate, timely and consistent with pharmaceutical regulation requirements. If the order appears unjustified, legal challenge is possible, but cooperation is usually the better first step. We advise on immediate obligations, communications, insurance and any claims against suppliers or contract manufacturers responsible for the defect.